Unilateral hand-foot syndrome: Does it take sides? Case report and literature review

Clinical Colorectal Cancer

Volumn 11, Issue 1, 2012, Pages 82-84

  Da Cruz, Livia Almeida ^a   Hoff, Paulo Marcelo Gehm ^a   Ferrari, Claudio Luiz Seabra ^a   Riechelmann, Rachel Sim̃es Pimenta ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Fluoropyrimidines; Hand foot syndrome

Indexed keywords

ALCOHOL; CAPECITABINE; CARCINOEMBRYONIC ANTIGEN; FLUOROURACIL; OXALIPLATIN;

ADULT; ALCOHOL CONSUMPTION; ANTIGEN DETECTION; CANCER CHEMOTHERAPY; CASE REPORT; CEREBROVASCULAR ACCIDENT; COLON ADENOCARCINOMA; COLON RESECTION; COLON TUMOR; COLONOSCOPY; COMPUTER ASSISTED TOMOGRAPHY; DIARRHEA; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; HAND FOOT SYNDROME; HUMAN; MALE; MUCOSA INFLAMMATION; POSTOPERATIVE COMPLICATION; REVIEW; SMOKING; WALKING AID;

EID: 84861547503     PISSN: 15330028     EISSN: 19380674     Source Type: Journal    
DOI: 10.1016/j.clcc.2011.05.004     Document Type: Article

References (25)

1. Zuehlke R. Erythematous eruption of the palms and soles associated with mitotane therapy. Dermatologica 1974; 148:90-2.
2. Baack B, Burgdorf W. Chemotherapy-induced acral erythema. J Am Acad Dermatol 1991; 24:457-61.
3. Degen A, Alter M, Schenck F, et al. The hand-foot-syndrome associated with medical tumor therapy: classification and management. J Dtsch Dermatol Ges 2010; 8:652-61.
4. Elasmar S, Saad E, Hoff P. Case report: hand-foot syndrome induced by the oral fluoropyrimidine S-1. Jpn J Clin Oncol 2001; 31:172-4.
5. Lacouture M, Wu S, Robert C, et al. Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib. Oncologist 2008; 13:1001-11.
6. Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors. Meta-Analysis Group in Cancer. J Clin Oncol 1998; 16:3537-41.
7. Walko C, Lindley C. Capecitabine: a review. Clin Ther 2005; 27:23-44.
8. Hoff P, Ansari R, Batist G, et al. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol 2001; 19: 2282-92.
9. Gressett S, Stanford B, Hardwicke F. Management of hand-foot syndrome induced by capecitabine. J Oncol Pharm Pract 2006; 12:131-41.
10. Abushullaih S, Saad E, Munsell M, et al. Incidence and severity of hand-foot syndrome in colorectal cancer patients treated with capecitabine: a single-institution experience. Cancer Invest 2002; 20:3-10.
11. Scheithauer W, McKendrick J, Begbie S, et al. X-ACT Study Group. Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, phase III trial. Ann Oncol 2003; 14:1735-43.
12. O'Shaughnessy J, Blum J. A retrospective evaluation of the impact of dose reduction in patients treated with Xeloda (capecitabine). Proc Am Soc Clin Oncol 2000; 19: 104A.
13. Lassere Y, Hoff P. Management of hand-foot syndrome in patients treated with capecitabine (Xeloda). Eur J Oncol Nurs 2004; 8:S31-40.
14. Kang Y, Lee S, Yoon D, et al. Pyridoxine is not effective to prevent hand-foot syndrome associated with capecitabine therapy: results of a randomized, doubleblind, placebo-controlled study. J Clin Oncol 2010; 28:3824-9.
15. Lacouture M, Reilly L, Gerami P, et al. Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib. Ann Oncol 2008; 19:1955-61.
16. Rosenbaum S, Wu S, Newman M, et al. Dermatological reactions to the multitargeted tyrosine kinase inhibitor sunitinib. Support Care Cancer 2008; 16:557-66.
17. Milano G, Etienne-Grimaldi M, Mari M, et al. Candidate mechanisms for capecitabine-related hand-foot syndrome. Br J Clin Pharmacol 2008; 66:88-95.
18. Yen-Revollo J, Goldberg R, McLeod H. Can inhibiting dihydropyrimidine dehydrogenase limit hand-foot syndrome caused by fluoropyrimidines? Clin Cancer Res 2008; 14:8-13.
19. Saif M, Elfiky A, Diasio R. Hand-foot syndrome variant in a dihydropyrimidine dehydrogenase-deficient patient treated with capecitabine. Clin Colorectal Cancer 2006; 6:219-23.
20. Jacobi U, Waibler E, Schulze P, et al. Release of doxorubicin in sweat: first step to induce the palmar-plantar erythrodysesthesia syndrome? Ann Oncol 2005; 16: 1210-1.
21. Horn T. Antineoplastic chemotherapy, sweat, and the skin. Arch Dermatol 1997; 133:905-6.
22. Disel U, Gürkut O, Abali H, et al. Unilateral hand-foot syndrome: an extraordinary side effect of capecitabine. Cutan Ocul Toxicol 2010; 29:140-2.
23. Narasimhan P, Narasimhan S, Hitti IF, et al. Serious hand-and-foot syndrome in black patients treated with capecitabine: report of 3 cases and review of the literature. Cutis 2004; 73:101-6.
24. Janusch M, Fischer M, Marsch W, et al. The hand-foot syndrome: a frequent secondary manifestation in antineoplastic chemotherapy. Eur J Dermatol 2006;16:494-9.
25. Saif M, Sandoval A. Atypical hand-and-foot syndrome in an African American patient treated with capecitabine with normal DPD activity: is there an ethnic disparity? Cutan Ocul Toxicol 2008; 27:311-5.